USA/India: Generics Cipla Receives Final Approval for Generic Enablex Tablets

Editor: Dominik Stephan

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Darifenacin Extended-Release Tablets, 7.5mg and 15 mg, from the United States Food and Drug Administration (USFDA).

Related Companies

(Source: Public Domain / CC0 )

Mumbai/India – Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg, are AB-rated generic equivalents of Allergan’s Enablex Tablets, 7.5mg and 15mg, and are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

The product will be launched immediately. Enablex Tablets and generic equivalents had US sales of approximately $85 million for the 12 month period ending June 2016, according to IMS Health.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent